feed,title,long_url,short_url
Nasdaq,Malaysia's Top Glove posts record profit for fourth consecutive quarter in Q2,https://www.nasdaq.com/articles/malaysias-top-glove-posts-record-profit-for-fourth-consecutive-quarter-in-q2-2021-03-09,https://j.mp/3t5YZbt
Nasdaq,Novartis: Phase III CANOPY-2 Trial Of Canakinumab Fails To Meet Primary Endpoint,https://www.nasdaq.com/articles/novartis%3A-phase-iii-canopy-2-trial-of-canakinumab-fails-to-meet-primary-endpoint-2021-03,https://j.mp/2OcKG6c
Nasdaq,Deutsche Post raises targets as ecommerce booms,https://www.nasdaq.com/articles/deutsche-post-raises-targets-as-ecommerce-booms-2021-03-09,https://j.mp/30oKZxc
Nasdaq,"GLOBAL MARKETS-Asian stocks recover on firmer futures, retreat in U.S. yields",https://www.nasdaq.com/articles/global-markets-asian-stocks-recover-on-firmer-futures-retreat-in-u.s.-yields-2021-03-09,https://j.mp/3ccPjoR
Nasdaq,Turkish lira claws back some losses after two-week slide,https://www.nasdaq.com/articles/turkish-lira-claws-back-some-losses-after-two-week-slide-2021-03-09,https://j.mp/3emQWDi
Nasdaq,ION Group launches public voluntary offer on Italy's Cerved at 9.50 euros/share,https://www.nasdaq.com/articles/ion-group-launches-public-voluntary-offer-on-italys-cerved-at-9.50-euros-share-2021-03-09,https://j.mp/3qwpR2R
Nasdaq,Novartis' canakinumab doesn't meet primary endpoint in phase III study,https://www.nasdaq.com/articles/novartis-canakinumab-doesnt-meet-primary-endpoint-in-phase-iii-study-2021-03-09,https://j.mp/38oCYNf
